查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1557324

脑脊髓液 (CSF) 管理市场 – 2024 年至 2029 年预测

Cerebrospinal Fluid (CSF) Management Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 136 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球脑脊髓液（CSF）管理市场预计将从2024年的819,534,000美元扩大到2029年的1,036,706,000美元，复合年增长率为4.81%。

脑脊髓液 (CSF) 存在于大脑和脊髓中，为大脑提供机械和免疫保护。各种管理装置，例如脑脊髓液引流系统和脑脊髓液分流器，控制脑脊髓液从身体心室的流动，并防止脑脊髓液不当积聚和水脑症。

新兴国家多家神经科医院的开拓以及对具有成本效益的治疗的持续投资正在推动市场扩张。此外，神经系统疾病盛行率的增加、老年人口增加对微创手术的高需求、可支配收入的增加以及医疗基础设施的进步也是促进脑脊髓液管理市场成长的因素之一。

此外，医院正在透过引入新产品和技术改进来治疗各种神经血管疾病，这可能会在整个预测期内提供良好的市场成长前景。根据美国美国神经病变的数据，全世界每 1000 名婴儿中就有 1 到 2 名出生时患有水脑症。

全球业务的最大限制之一是合格的神经外科医生的短缺，其数量不足以满足快速增长的老年人口对优质医疗保健的需求。与脑脊髓液分流和感测器相关感染疾病相关的问题日益增多，预计将成为预测期内限制全球脑脊髓液管理市场成长的两个主要问题。除此之外，设备的高成本和脑脊髓液分流引起的感染疾病阻碍了市场成长。

全球脑脊髓液 (CSF) 管理市场驱动因素：

  • 神经和脑部疾病盛行率的增加预计将加速市场扩张。

脑脊髓液充当缓衝垫，保护大脑和脊髓免受突然损伤。它还可以去除大脑周围不必要的成分，帮助中枢神经系统正常运作。脑脊髓液管理可防止渗漏影响大脑和脊髓。随着脑损伤和神经病变的迅速增加，分流器和外部引流系统（EDS）等设备的需求预计也会增加。

根据世界神经病学联合会 2023 年 10 月的新闻稿，神经系统疾病是全球第二大死亡和残疾原因。根据该联合会最近的一项研究，世界上近 40% 的人口患有某种形式的神经系统疾病。到 2050 年，这一数字预计将增加一倍，报告的病例主要发生在低收入和中等收入国家，目前这些国家占全球神经系统死亡的 84%。

全球脑脊髓液（CSF）管理市场細項分析

  • 据估计，分流器占了很大的市场。

依产品类型划分，全球脑脊髓液管理市场分为外部引流系统和分流器。由于世界各地进行的分流手术数量不断增加，以及由于分流失败或感染而导致的再次手术数量不断增加，分流预计将在脑脊髓液管理行业中占据主导地位。现代分流术的好处，例如减少再次手术的可能性和缩短平均住院时间，正在刺激该领域的扩张。

  • 儿科产品预计将占据重要的市场占有率。

按最终用户划分，全球脑脊髓液 (CSF) 管理市场分为成人、儿童和老年。在预测期内，由于先天性水脑症的盛行率不断增加以及儿科族群中进行的分流手术数量不断增加，预计儿科类别将占据重要的市场占有率。

  • 在规定的时限内，医院将占据重要的市场占有率。

全球脑脊髓液 (CSF) 管理市场按行业分析为医院、诊所等。由于人口老化中与脑脊髓液管理相关的住院病例数量较多，医院部门占据了很大的市场占有率，预计在预测期内将以最快的速度扩张。

亚太地区预计将经历显着成长。

按地区划分，全球市场分为北美、南美、欧洲、中东和非洲以及亚太地区，其中亚太地区预计成长率最高。由于中国先天性水脑症盛行率上升以及各国老年人口不断增加，亚太国家的医疗旅游正在发展，推动了该地区市场的扩张。

此外，持续的研究合作和投资以加强神经系统疾病的治疗预计也将推动该地区的市场扩张。例如，由生物技术部实施并由印度政府支持的失智症科学计划，旨在研究老龄化人口中失智症的盛行率。

同样，在研究机构加强神经系统疾病治疗的策略性努力的推动下，北美预计将出现显着增长。食品药物管理局(FDA) 等主要机构正在核准针对老龄化人口的新神经病变治疗方法，从而提供新的成长前景。此外，美敦力 (Medtronic)、强生 (Johnson &Johnson) 和 IntegraLifeSciences 等主要市场参与者的成熟存在也进一步推动了区域市场扩张。

全球脑脊髓液（CSF）管理主要市场开拓：

  • 2023年12月，Plus Therapeutic Inc.将与K2bio伙伴关係，为中枢神经系统癌症患者进行脑脊髓液癌症检测和分子生物标记检测。
  • 2023年6月，罗氏将推出“Elecsys(R) beta-淀粉样蛋白(1-42) CSF II (Abeta42)”和“Elecsys(R) Total-Tau CSF检测”，用于测量55岁及以上成年人类的阿兹海默症病理学已获得 FDA 510(k) tTau 许可。
  • 2023 年 1 月，百健 (Biogen) 和 Arion Therapeutics 签署了开发 ThecaFlex DRx (TM) 系统的许可和协议，该系统是一种植入式医疗设备，可对脑脊髓液进行ASO（反义寡核苷酸）治疗。此次协议将优化百佳泰在脑脊髓液输送技术的经验，并改善神经系统疾病患者的治疗体验。

全球脑脊髓液（CSF）管理市场细分与分析如下：

依产品类型

  • 脑脊髓液分流术
  • 外部排水系统

按最终用户

  • 儿科的
  • 成人用
  • 对于老年人

按行业分类

  • 医院
  • 诊所
  • 其他的

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 其他中东/非洲
  • 沙乌地阿拉伯
  • 以色列
  • 其他的
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 台湾
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球脑脊髓液（CSM）管理市场：依产品类型

  • 介绍
  • 脑脊髓液分流术
  • 外部排水系统

第六章全球脑脊髓液（CSM）管理市场：依最终使用者分类

  • 介绍
  • 小儿科
  • 成人用
  • 老年病

第七章全球脑脊髓液（CSM）管理市场：依产业分类

  • 介绍
  • 医院
  • 诊所
  • 其他的

第八章全球脑脊髓液（CSM）管理市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Medtronic
  • Integra LifeSciences
  • Johnson & Johnson MEDTECH
  • B. Braun Melsungen AG
  • Spiegelberg GmbH & Co. KG（Acquired by SHS Medizintechnik Holding GmbH）
  • Sophysa（A subsidiary of tkb group）
  • Natus Medical Incorporated（Acquired by ArchiMed Group）
  • Argi Grup
  • Moller Medical GMBH
  • Delta Surgical
  • Wellong Instruments Co., Ltd.
简介目录
Product Code: KSI061611877

The global cerebrospinal fluid (CSF) management market is poised to expand from US$819.534 million in 2024 to US$1,036.706 million in 2029 at a 4.81% CAGR.

Cerebrospinal fluid (CSF) is found in the brain and spinal cord that protects the brain mechanically and immunologically. Various management devices, such as CSF drainage systems and CSF shunts, control the flow of CSF away from the ventricles in the body, preventing inappropriate CSF accumulation and hydrocephalus.

Developing several neuro-hospitals in emerging countries and ongoing investments for cost-effective treatment drive market expansion. Furthermore, the growing prevalence of neurological disorders, the high demand for minimally invasive surgeries fuelled by the growing geriatric population, rising disposable incomes, and advancing healthcare infrastructure are among the other contributing factors to the cerebrospinal fluid management market growth.

Moreover, hospitals are treating various neurovascular illnesses due to introducing new products and technical improvements that will give lucrative market growth prospects throughout the projected period. According to the National Institute of Neurological Disorders and Stroke, one to two out of every 1000 babies worldwide are born with hydrocephalus.

One of the most significant constraints on global business is the scarcity of qualified neurosurgeons, whose existing number is insufficient to meet the demand for quality healthcare in a rapidly rising senior population. Rising problems connected with CSF shunts and sensor-related infections are two major issues predicted to limit the worldwide cerebrospinal fluid management market's growth in the projected period. Apart from that, the market's growth is hampered by the high cost of devices and the infections generated by CSF shunts.

Global Cerebrospinal Fluid (CSF) Management Market Drivers:

  • The growing prevalence of neurological & brain disease is expected to accelerate the market expansion.

The cerebrospinal fluid protects the brain and spinal cord from sudden injury by acting as a cushion. It also removes unnecessary elements surrounding the brain, assisting in the proper functioning of the central nervous system. CSF management prevents any leaks that might affect the brain or spinal cord. With the booming strength of brain injuries and neurological disorders, the demand for devices such as shunts and external drainage systems (EDS) is also anticipated to increase.

According to the October 2023 press release of the World Federation of Neurology, neurological disorders account for the second highest causes of death and disability globally. As per the federation's recent study, nearly 40% of the global population suffers from some neurological condition; by 2050, the projected number will double, with major cases being reported in low to middle-income countries, which currently account for 84% of all neurological deaths occurring globally.

Global Cerebrospinal Fluid (CSF) Management Market Segment Analysis

  • Shunts are estimated to account for a considerable share of the market.

By product type, the global cerebrospinal fluid management market is segmented into external drainage systems and shunts. Shunts are expected to dominate the CSF management industry owing to the rising number of shunting procedures conducted worldwide and the increasing number of revision shunt surgeries due to their malfunction and infection. The advantages of modern shunts, such as the reduced likelihood of revision surgery and a shorter average hospital stay, fuel the segment's expansion.

  • Pediatric is projected to account for a considerable market share.

By end-users, the global cerebrospinal fluid (CSF) management market is divided into adult, pediatric, and geriatric. During the forecast period, the paediatric category is estimated to account for a considerable market share fuelled by the increased prevalence of congenital hydrocephalus and the increasing number of shunting procedures performed in the paediatric population.

  • Hospitals will account for a remarkable market share during the given timeframe.

The global cerebrospinal fluid (CSF) management market is analyzed by industry into hospitals, clinics, and others. Due to the large number of hospital cases linked to CSF management in the aging population, the hospital segment is anticipated to account for a sizable market share and expand at the quickest rate over the projection period.

Asia Pacific is poised for significant growth.

By geography, the global cerebrospinal fluid (CSF) management market is segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific, where the latter is expected to grow at the highest rate. The developing medical tourism in Asia Pacific countries, fuelled by the rising prevalence of congenital hydrocephalus in China and the growing geriatric population in various nations, are driving regional market expansion.

Moreover, the ongoing research collaboration and investment to bolster treatment for neurological disorders are also expected to drive the regional market expansion. For instance, the "Dementia Science Program" implemented by the Department of Biotechnology and backed up by the Indian government aimed to study the prevalence rate of dementia in the aging population.

Likewise, North America is expected to grow considerably, fuelled by the strategic efforts undertaken by research institutes to bolster the treatment of neurological conditions. Major organizations, namely the Food and Drug Administration, are approving new neuropathy treatments for aging populations, which has provided new growth prospects. Additionally, the well-established presence of major market players, namely Medtronic, Johnson & Johnson, and IntegraLifeSciences, is acting as additional driving factors for regional market expansion.

Global Cerebrospinal Fluid (CSF) Management Key Market Development:

  • In December 2023, Plus Therapeutic Inc. formed a partnership with K2bio to implement CSF cancer and molecular biomarker testing for CNS cancer patients. The respective processing & testing partnership forms part of Plus Therapeutics' strategy to address the therapeutic and diagnostics needs of CAN patients.
  • In June 2023, Roche received the FDA's 510(k) clearance for its "Elecsys(R) beta-Amyloid (1-42) CSF II (Abeta42)" and "Elecsys(R) Total-Tau CSF assays (tTau)" which would measure Alzhamier's pathology in adults aged 55 years and above. The clearance further adds to Roche's portfolio for defining the pathological process for Alzheimer's amyloid plaques, neurodegeneration, and tau tangles.
  • In January 2023, Biogen Inc. formed a license and collaboration agreement with Alyone Therapeutics for the development of the latter's "ThecaFlex DRx(TM) System" into an implantable medical device that would deliver ASO (Antisense Oligonucleotide) therapies to cerebrospinal fluid. The agreement will optimize Alyone's experience in CSF delivering technology, thereby improving the treatment experience for patients suffering from neurological conditions.

The Global Cerebrospinal Fluid (CSF) Management market is segmented and analyzed as follows:

By Product Type

  • CSF Shunts
  • External Drainage System

By End User

  • Pediatric
  • Adult
  • Geriatric

By Industry

  • Hospital
  • Clinics
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL CEREBROSPINAL FLUID (CSM) MANAGEMENT MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. CSF Shunts
  • 5.3. External Drainage System

6. GLOBAL CEREBROSPINAL FLUID (CSM) MANAGEMENT MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Pediatric
  • 6.3. Adult
  • 6.4. Geriatric

7. GLOBAL CEREBROSPINAL FLUID (CSM) MANAGEMENT MARKET BY INDUSTRY

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. GLOBAL CEREBROSPINAL FLUID (CSM) MANAGEMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. Israel
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Medtronic
  • 10.2. Integra LifeSciences
  • 10.3. Johnson & Johnson MEDTECH
  • 10.4. B. Braun Melsungen AG
  • 10.5. Spiegelberg GmbH & Co. KG (Acquired by SHS Medizintechnik Holding GmbH)
  • 10.6. Sophysa (A subsidiary of tkb group)
  • 10.7. Natus Medical Incorporated (Acquired by ArchiMed Group)
  • 10.8. Argi Grup
  • 10.9. Moller Medical GMBH
  • 10.10. Delta Surgical
  • 10.11. Wellong Instruments Co., Ltd.